AMRN logo

AMARIN CORP PLC -ADR

AMRNNASDAQ
๐Ÿ† #2810 by market capEarnings Oct 27US Equity
$14.01โ–ผ $0.10 (โˆ’0.71%)
Market closed ยท at close
1hโ€”
24hโ–ผ 0.7%
7dโ–ผ 2.7%
14dโ–ผ 1.2%
30dโ–ผ 4.8%
1yโ–ผ 6.4%
๐ŸฆMarket Cap
$5.92B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-37.6%
Declining
๐Ÿ“ŠGross Margin
41.0%
Healthy
๐Ÿ’ตFCF Margin
20.7%
Strong
โš–๏ธP/S Ratio
2.2x
Cheap
Otter Score
53
Weak

Trading Snapshot

Day Range
$13.84 โ€“ $14.07
52-Week Range
$12.96 โ€“ $20.90
Volume
$3.25B
Avg Volume
$3.51B
Shares Outstanding
422.5M
Next Earnings
Sep 12, 2026

Fundamentals Snapshot

Annual Revenue
$214M
Last Q Revenue
$42M
P/E Ratio
โ€”
P/S Ratio
2.2x
EPS (TTM)
$-0.07
Dividend Yield
โ€”

Why Investors Own AMRN

  • โœ“High-growth profile โ€” revenue up +47.2% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 44% gross margin and 6% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$214Mโ–ฒ +47.7% YoY
Gross Margin (TTM)
44.4%โ–ฒ +2.5% YoY
Operating Income (TTM)
$68Mโ–ฒ +47.7% YoY
Free Cash Flow (TTM)
$13Mโ–ฒ +47.7% YoY

About AMARIN CORP PLC -ADR

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
53/100

Analyst Ratings

โ“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold2
Sell2
Strong Sell2
Ratings as of Aug 2026

Latest News & Updates